OCGN · Healthcare · $353M
After-hours $1.04+0.97%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Short Float 31.1% · biweekly · settled 26.08.31
Among 327 Biotechnology peers
Quarterly Revenue Growth
“이번 분기는 FDA가 OCU410의 임상 3상을 승인하고 신속심사 성격의 RMAT 지위까지 부여한 점이 가장 큰 변화예요.”
In the company's words · 2026 2분기 earnings call